My thoughts, BUY, WF10 top line results are to be released mid-February. Nuvo Research currently sitting on $5 CASH per share, no debt, revenue generating drugs plus potential blockbuster drug WF10. Again, my thoughts, BUY, this stock is on sale based on the big picture.